FMP
Liminal BioSciences Inc.
LMNL
NASDAQ
Inactive Equity
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
8.5 USD
0.01 (0.118%)
Latest LMNL News
Zacks Investment Research
Jul 13, 2023
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Market Watch
Jul 12, 2023
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.
InvestorPlace
Apr 5, 2023
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.
Market Watch
Apr 5, 2023
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.
Seeking Alpha
Mar 17, 2023
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.
PRNewsWire
Jan 19, 2023
Liminal BioSciences to Present at BIO CEO & Investor Conference
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
Seeking Alpha
Nov 13, 2022
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
Seeking Alpha
May 13, 2022
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
PRNewsWire
May 9, 2022
Liminal Biosciences to Present at Upcoming Investor Conferences
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).
Benzinga
Jan 20, 2022
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia. The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.
